- Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
- Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
- Editas Medicine Announces First Quarter 2024 Results and Business Updates
- Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
- Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
- Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
- Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
- Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
- Editas Medicine to Participate in Upcoming Investor Conferences
- Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
More ▼
Key statistics
On Friday, Editas Medicine Inc (EDIT:NSQ) closed at 5.20, 5.91% above its 52-week low of 4.91, set on May 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.19 |
---|---|
High | 5.42 |
Low | 5.16 |
Bid | 5.18 |
Offer | 5.27 |
Previous close | 5.17 |
Average volume | 1.90m |
---|---|
Shares outstanding | 82.24m |
Free float | 81.95m |
P/E (TTM) | -- |
Market cap | 427.64m USD |
EPS (TTM) | -2.10 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
More ▼